Crohn’s Disease: A Curable Disease Held Hostage?

Abstract

The current focus of Crohn’s disease therapy has been long sclerosed. Biologics produce temporary remissions in 40% of cases. They have yet to induce permanent remissions. FDA’s reliance on clinical validation through comparative, placebo controlled, double-blinded studies has created an impediment to acceptance of divergent alternated therapies as being within the standard of care. In so doing, FDA has basically has surrendered the therapeutic dialogue of Crohn’s disease to those who can pay from such studies.